

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

620-445

Unknown

APPLICANT

BERNARDS ET AL.

(Use several sheets if necessary)

FILING DATE

TC/A.U.

July 24, 2006

Unknown

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Partial International Search Report for PCT/EP2005/000937.
	Ikeda et al., <i>Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor</i> , Immunity, vol. 6, no. 2, February 1997, pp. 199-208, XP002216277.
	Plumb et al., <i>Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101</i> , Molecular Cancer Therapeutics, vol. 2, no. 8, August 2003, pp. 721-728, XP002372785.
	Freemantle et al., <i>Retinoids in cancer therapy and chemoprevention: Promise meets resistance</i> , Oncogene, vol. 22, no. 47, 20 October 2003, pp. 7305-7315, XP008061601.
	Brummelkamp et al., <i>Stable Suppression of Tumorigenicity by Virus-Mediated RNA Interference</i> , Cancer Cell, vol. 2, no. 3, September 2002, pp. 243-247, XP009006464.
	Epping et al., <i>The Human Tumor Antigen Prame is a Dominant Repressor of Retinoic Acid Receptor Signaling</i> , Cell, vol. 122, no. 6, 23 September 2004, pp. 835-847, XP008061580.
	Tajeddine et al., <i>Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo</i> , Cancer Research, vol. 65, no. 16, August 2005, pp. 7348-7355, XP002372786.
	Product: sc-37322, Online Catalog of Santa Cruz Biotechnology, Inc., 2004, XP002372787.

***Examiner**

Date Considered